Scarica l'app Stockscreener
13.56
0.07%
0.010
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Storia dei dividendi
Precedente Chiudi:
$13.55
Aprire:
$13.55
Volume 24 ore:
2.22M
Relative Volume:
0.34
Capitalizzazione di mercato:
$3.56B
Reddito:
$6.16B
Utile/perdita netta:
$246.00M
Rapporto P/E:
14.45
EPS:
0.9387
Flusso di cassa netto:
$708.00M
1 W Prestazione:
+0.30%
1M Prestazione:
+0.15%
6M Prestazione:
+58.78%
1 anno Prestazione:
+39.79%
Intervallo 1D:
$13.54
$13.57
Intervallo di 1 settimana:
$13.51
$13.57
Portata 52W:
$5.69
$13.60
Organon Co Stock (OGN) Company Profile
Nome
Organon Co
Settore
Industria
Telefono
551-430-6000
Indirizzo
30 HUDSON STREET, JERSEY CITY
Compare OGN vs LLY, JNJ, ABBV, MRK, NVS
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
OGN
Organon Co
|
13.55 | 3.56B | 6.16B | 246.00M | 708.00M | 0.9387 |
LLY
Lilly Eli Co
|
1,148.52 | 1.07T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
256.42 | 640.91B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
251.06 | 453.91B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
130.22 | 322.95B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
156.14 | 296.72B | 54.66B | 13.58B | 16.05B | 7.0171 |
Organon Co Stock (OGN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-09 | Iniziato | Barclays | Underweight |
| 2025-10-27 | Downgrade | Piper Sandler | Overweight → Underweight |
| 2025-05-02 | Downgrade | Evercore ISI | Outperform → In-line |
| 2024-09-06 | Downgrade | JP Morgan | Neutral → Underweight |
| 2023-11-03 | Downgrade | Goldman | Buy → Neutral |
| 2023-09-21 | Iniziato | Barclays | Overweight |
| 2023-03-16 | Iniziato | Raymond James | Outperform |
| 2022-10-14 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-09-06 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-08-05 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-04-27 | Iniziato | Goldman | Buy |
| 2022-04-06 | Ripresa | Morgan Stanley | Equal-Weight |
| 2021-10-07 | Iniziato | Piper Sandler | Neutral |
| 2021-09-01 | Iniziato | BofA Securities | Buy |
| 2021-07-22 | Iniziato | Citigroup | Buy |
| 2021-06-15 | Iniziato | JP Morgan | Neutral |
| 2021-06-11 | Iniziato | Morgan Stanley | Equal-Weight |
| 2021-06-10 | Iniziato | Evercore ISI | Outperform |
Mostra tutto
Organon Co Borsa (OGN) Ultime notizie
Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
OGN|Organon & Co|Price:13.535|Chg%:+0.015 - TradingKey
India healthcare M&A hits record value as pharma takes centre stage - DealStreetAsia
OGN Looks 6.8% Undervalued on GF Value™ - GuruFocus
Organon & Co (OGN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Organon & Co. (OGN) Q1 2023 Earnings ReportResults, Call & Slides - TipRanks
OGN|Organon & Co|Price:13.520| - TradingKey
Organon & Co (OGN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Organon & Co (OGN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
OGN Stock Set For Blastoff? Sun Pharma Offers 24% Premium In All-Cash Buyout Deal - Stocktwits
Organon & Co. (OGN) Q4 2023 Earnings ReportResults, Call & Slides - TipRanks
Organon & Co. (1OGN) Q4 2023 Earnings ReportResults, Call & Slides - TipRanks
Organon & Co. (OGN) Q4 2025 Earnings ReportResults, Call & Slides - TipRanks
Organon & Co. (1OGN) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks
Organon & Co. (1OGN) Q4 2024 Earnings ReportResults, Call & Slides - TipRanks
Organon & Co. (1OGN) Q1 2024 Earnings ReportResults, Call & Slides - TipRanks
Organon & Co. (1OGN) Q3 2025 Earnings ReportResults, Call & Slides - TipRanks
Organon & Co. (OGN) Investigation: Bronstein, Gewirtz & Grossman - The National Law Review
India’s pharma M&A market hits four-year high on blockbuster deals - The Pharma Letter
Sun Pharma Clears Key Milestone as Organon Shareholders Back USD 11.75 Billion Buyout - Medical Dialogues
Sun Pharma Receives Organon Shareholder Approval for Proposed Acquisition - Machine Maker
Organon & Co. (OGN) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks
Organon shareholders approve Sun Pharma acquisition proposal - Indian Pharma Post
Organon & Co. (OGN) Q1 2024 Earnings ReportResults, Call & Slides - TipRanks
Organon & Co. (OGN) Q4 2024 Earnings ReportResults, Call & Slides - TipRanks
Organon & Co. (OGN) Q3 2025 Earnings ReportResults, Call & Slides - TipRanks
Organon & Co. (1OGN) Q4 2025 Earnings ReportResults, Call & Slides - TipRanks
New Analysis of Phase 3 Pooled Data for Organon's VTAMA® (tapinarof) cream, 1%, Demonstrates Early, Consistent Improvements in Atopic Dermatitis Patients Across Pediatric Age Groups and in Adults1 - Lelezard
Organon's VTAMA Skin-Clearance Response Reached 56.3% in Ages 2–6 at Week 8 - Stock Titan
Sun Pharma gets Organon shareholders’ nod for its $11.75-bn acquisition proposal - BusinessLine
Organon & Co. (OGN) 8-K Filing: Key Stockholder Vote Results and Company Information – July 2026 - Minichart
Organon shareholders approve merger with Sun Pharma - Fortune India
Organon Shareholders Approve Sun Pharma Merger, Deal Nears Completion - outlookbusiness.com
Sun Pharma Stock Slips as Organon Holders Approve Merger - Equitypandit
Organon shareholders approve Sun Pharma's $11.75-bn acquisition proposal - The Economic Times
Organon Shareholders Approve Sun Pharma’s USD 11.75-bn Acquisition Proposal - HDFC Sky
Sun Pharma Moves Closer To Record $12 Billion Organon Deal After Shareholders Approval - NDTV Profit
OGN|Organon & Co|Price:13.520|Chg%:-0.035 - TradingKey
Sun Pharma inches closer to biggest-ever buyout as Organon shareholders approve merger - Moneycontrol.com
Sun Pharma receives Organon shareholders approval for merger - Business Standard
Sun Pharma moves closer to Organon acquisition as shareholders approve deal; stock in focus - Upstox
Organon Shareholders Endorse Merger with Sun Pharmaceutical Holdings USA in July 2026 Vote - Kalkine Media
Organon & Co. Shareholders Clear Sun Pharma Merger Deal - TradingView
Organon holds special shareholder meeting on merger agreement proposal - Bitget
Organon (OGN) Stock Looks Below Fair Value Despite Weak Earnings Quality - simplywall.st
Organon (OGN) Proxy filing Summary - Quartr
ORGANON CANADA ANNOUNCES THE APPOINTMENT OF DOMINIC BÉGIN AS PRESIDENT AND MANAGING DIRECTOR - marketscreener.com
Press Release: ORGANON CANADA ANNOUNCES THE APPOINTMENT OF DOMINIC BÉGIN AS PRESIDENT AND MANAGING DIRECTOR - Moomoo
Sun Pharma to acquire US-based Organon in nearly $11.75 billion deal - DD News
Price-Driven Insight from (OGN) for Rule-Based Strategy - Stock Traders Daily
Organon stock trades steady as women’s health focus meets mixed earnings momentum - Ad-hoc-news.de
Organon Co Azioni (OGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Organon Co Azioni (OGN) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Holzbaur Lynette | SVP and Corporate Controller |
May 06 '26 |
Buy |
13.35 |
26,448 |
353,080 |
52,851 |
| Drinane Juliana Papa | Interim Head of Mfg & Supply |
Mar 31 '26 |
Option Exercise |
0.00 |
16,451 |
0 |
36,687 |
| Arjona Ferreira Juan Camilo | Head of R&D & CMO |
Mar 31 '26 |
Option Exercise |
0.00 |
13,431 |
0 |
34,867 |
| Karp Daniel | Executive VP, Corp. Dev. |
Mar 31 '26 |
Option Exercise |
0.00 |
18,053 |
0 |
71,653 |
| Stahler Rachel A | Chief Information Officer |
Mar 31 '26 |
Option Exercise |
0.00 |
18,867 |
0 |
120,322 |
| WALSH MATTHEW M | Chief Financial Officer |
Mar 31 '26 |
Option Exercise |
0.00 |
33,593 |
0 |
220,126 |
| Falcione Aaron | Chief Human Resources Officer |
Mar 31 '26 |
Option Exercise |
0.00 |
17,925 |
0 |
105,265 |
| Weaver Kirke | Gen. Counsel & Corp. Secy. |
Mar 31 '26 |
Option Exercise |
0.00 |
18,513 |
0 |
96,147 |
| Nisita Vittorio | Head of Global Business Svcs |
Mar 31 '26 |
Option Exercise |
0.00 |
13,000 |
0 |
73,494 |
| Holzbaur Lynette | SVP and Corporate Controller |
Mar 31 '26 |
Option Exercise |
0.00 |
10,967 |
0 |
28,316 |
0.48%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):